KUALA LUMPUR, April 28 (Bernama) -- Tricor Group and the Financial Times Board Director Programme have co-released the inaugural 2021 Asia Pacific Board Director Barometer Report, uncovering corporate board sentiments on COVID-19 disruptions globally with focus on Singapore and other APAC markets.
According to the Report, corporate boards struggle to keep pace with rising digital adoption and transformation pressures against the COVID-19 pandemic turbulent headwinds; business continuity planning (BCP) and corporate governance, risk & compliance (GRC) are weighing on board directors, rising to the top of corporate board priorities;
Corporate boards are not equipped to support effective hybrid meeting models, which are expected be the most favoured operating model post-pandemic; the digital divide continues to widen, and corporate boards are falling behind, highlighting operational and security risks and inefficiencies; and, gaps in cybersecurity threaten corporate board operations and integrity.
The Report reveals sentiments and actions of global board directors in key areas of digital transformation, cybersecurity, board operations, corporate GRC and BCP.
According to a statement, the sampling focuses largely on key markets in APAC (including mainland China, Hong Kong SAR, Malaysia, Singapore, Thailand, Vietnam, Japan and Australia) and also incorporates comparative samples from the Americas, Europe and Africa.
Overall, confidence on the handling of the crisis is mixed in APAC and there’s significant room for improvement in some markets: 71 per cent of board directors in Singapore said they felt positive about the way their boards responded, compared to mainland China (68 per cent), Malaysia (56 per cent), Thailand (52 per cent), Hong Kong (51 per cent), Australia (50 per cent), Japan (45 per cent) and Vietnam (42 per cent).
Corporate boards are unprepared to meet security and efficiency requirements for virtual meetings – both currently and post-pandemic, with only two per cent of boards in Singapore (vs five per cent globally) are currently meeting fully in-person, and only 11 per cent of boards in Singapore (vs 12 per cent globally) plan to meet fully in-person post-pandemic.
-- BERNAMA
Wednesday 28 April 2021
GMO RESEARCH TO LAUNCH NEW SERVICE BRAND "MO LITE"
The fastest, most cost-effective solution for conducting online surveys in APAC
TOKYO, April 28 (Bernama-GLOBE NEWSWIRE) -- GMO Research, Inc. (https://gmo-research.com/), a leading online research solution platform provider in the APAC region, has rolled out a new initiative to support companies in conducting online research projects with the fastest and most cost-effective turnaround in APAC.
There is an increasing demand for DIY market research tools that allow companies to conduct survey research remotely and at low costs. But when a company really starts to plan a research project, there are some common obstacles. Firstly, the targeted audience is limited to the company’s own service and/or product line, so the company cannot collect a larger number of responses. Secondly, recruiting people for a survey is a time-consuming and costly process. And lastly, localizing questionnaires, ensuring they align with local law, and checking that the contents address the cultural and linguistic background correctly takes a great deal of effort.
To address these issues, GMO Research has developed “MO Lite”, a new service that enables companies to link their own using DIY market research tools to recruit survey respondents directly from one of the largest pool of panelists in APAC, with a price less as USD 10 cent per question, that comes with full support from APAC local experts.
* USD 300 minimum fee will be included.
Takashi Ito, Chief Global Officer of GMO Research, Inc., comments: “With the rising demand for quick and cost-efficient choices for conducting surveys, it just came naturally to us that we would connect the largest consumer panel network in APAC with the most commonly used free survey tool, to bring great value to the market. We are confident that MO Lite can serve as one of the most viable options for conducting surveys in APAC. It is obviously the fastest, most cost-effective, and most reliable solution.”
For questions & inquiries: https://gmo-research.com/services/diy-survey-sampling
MO Lite inquiries:
MO Lite Project Team
Email: info@gmo-research.jp
Advantages of using MO Lite:
(1) Surveys can be conducted on people other than your own target audience
(2) Surveys can be sent out as soon as one business day after application.
(3) You can distribute to more than 200 pre-targeted attributes* at no additional cost.
* Targeted attributes are the attributes of monitors that have been databased through a large-scale screening survey conducted in advance by the Asia Cloud Panel.
About GMO Research:
GMO Research offers an all-in-one online research solution platform that allows direct access to one of the largest consumer panel networks in APAC: Asia Cloud Panel. Asia Cloud Panel currently consists of over 40 million online panelists, ranging from consumers to CEOs, across 15 APAC markets. GMO Research is part of and backed by GMO Internet Group, one of the largest internet conglomerates in Japan, specializing in a number of internet-related technologies. GMO Internet Group has the number one Japanese market share in internet security, payment processing, e-commerce solutions, web hosting, domain, and FX trading.
To find out more about GMO Research, visit https://gmo-research.com.
GMO Internet Group
GMO Internet Group is an Internet service industry leader, developing and operating Japan’s most widely used domain, hosting & cloud, ecommerce, security, and payment solutions. The Group also includes the world’s largest online FX trading platform, as well as online advertising, Internet media, and cryptoassets related services. GMO Internet, Inc. (TSE: 9449) is headquartered in Tokyo, Japan. For more information, please visit https://www.gmo.jp/en/.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8aab8aba-6299-4d0f-b36e-16f836d0a5a0
SOURCE : GMO Internet, Inc.
JOBDIVA MAKES HIRING MORE EFFICIENT BY INTEGRATING WITH JOBS ON FACEBOOK
NEW YORK, April 28 (Bernama-GLOBE NEWSWIRE) -- JobDiva is proud to announce an integration with Jobs on Facebook—one of the first integrations of its kind.
Jobs on Facebook makes it simple for employers and recruiters to post jobs, manage applications and communicate with candidates more easily. By synchronizing job openings, JobDiva’s integration with Jobs on Facebook empowers businesses to reach candidates where they are spending significant amounts of time.
“At JobDiva, we are focused on reducing unemployment during these uncertain times, as well as matching the workforce with their desired opportunities by maximizing our clients’ capabilities—and doing so quickly, in the interest of the public at large,” said Gus Samra, JobDiva’s Chief Revenue Officer. “JobDiva’s integration with Jobs on Facebook is a signal example of our commitment to talent and client success, and we’re ecstatic to offer this integration.”
About JobDiva: JobDiva, the leading global ATS, is delivered to clients via the cloud. JobDiva stands as the top-tier ATS, defining the path of innovation in staffing technology.
Contact:
Bella Chen
Head of Marketing, JobDiva
Bella.chen@jobdiva.com
+1 212-384-6566
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/65890c74-c25d-4a3c-a1a1-b11802201711
SOURCE : JobDiva
ANALYTICA ANNOUNCES EXPANSION OF ENHANCED INFUSION SYSTEM INTO MIDDLE EAST
Analytica signs agreement with Marwa for distribution, marketing and sales of the Enhanced Infusion System (EIS) in Egypt, Bahrain, Iran, Iraq, Jordan, Kuwait, Lebanon, Saudi Arabia and United Arab Emirates.- Patented IV add-in infusion system reduces infection and embolism risk and saves medical staff time for an overall lower total cost than existing equipment and practices.
BRISBANE, Australia, April 28 (Bernama-GLOBE NEWSWIRE) -- Analytica Limited (ASX:ALT), the Australian developer of the Enhanced Infusion System (EIS) and PeriCoach® pelvic floor exercise system for the treatment of stress urinary incontinence, has entered into an agreement with Marwa’s Office for Export & Import Medical Supplies (Marwa) to distribute, market and sell the EIS to hospital systems in Egypt, Bahrain, Iran, Iraq, Jordan, Kuwait, Lebanon, Saudi Arabia and United Arab Emirates.
The EIS technology was developed by Analytica under the project names AutoStart and AutoFlush and has been sold in Australia with the trade name FirstFlow™,¹ under limited license. EIS combines the AutoStart and AutoFlush patented technologies into a simple and inexpensive solution.
The patented float system automatically restarts IV fluid flow following medication delivery, thereby saving healthcare workers’ time, reducing hospital costs and preventing the adverse events associated with air embolism and failure of Peripheral Intravenous Catheters (PIVC). The EIS reacts immediately, silently and without intervention or programming. It can be retrofitted to any existing infusion system design and can work in harmony with and improve the capability of any infusion pump or ‘bag’ infusion system, regardless of sophistication.
Use of the EIS uniquely allows a completely closed infusion system, with integrity achieved by reducing the interactions believed to cause mechanical and vascular complications as well as good flushing and/or patency practice.
The EIS has an Australian TGA ARTG registration and USFDA 510(k) clearance. It is fully compliant with ISO 8536 infusion system and other relevant standards.
The EIS can markedly reduce legal risks by addressing multiple factors that can impact patients, clinicians and hospitals, including:
- Air Embolism – The EIS has a large and heavy float valve ensuring complete, long-term seal. The unique float maintains a seal even at extreme angles (up to 60 degrees from horizontal), making the device usable in ambulances, retrieval and military situations and reducing the risk of mortality and morbidity associated with air embolism.
- Open/Closed Delivery System – The needle-free access port is the only entry point, with only one syringe necessary per medication event. Using the existing 1L IV bag means replacement is less frequent than 100mL pre-mix bags, saving time and money and reducing the risk of contamination and infection.
- Syringe Flush – This feature eliminates the requirement to introduce an additional flushing syringe and bolus. Flushing prevents interactions between incompatible fluids/medications, thus reducing the risk of cross contamination and strengthening infection control.
- Catheter Flush – This feature reduces the risk of PIVC failure with the automatic, immediate restart of IV flow after medication delivery, which allows continuous maintenance flow to the flush line and catheter. This also maintains catheter patency by preventing internal luminal occlusion.
- Medication Dilution – The Interrupted Therapy feature allows the introduction of medication through EIS to accurately measure IV fluid mix rather than 3-way valve and bags.
- Infection Risk – Observational studies demonstrate high incidence of non-conformance to hand washing and flushing protocol. EIS limits access and infection opportunity.
- Flushing pressure – Bolus flush of catheter may vary based on syringe size and pressure. The proprietary float design ensures constant flushing pressure, reducing the risk of PIVC failure.
Given the health and legal risk-reduction features of the EIS, the home-based hospital care market represents a growth opportunity globally. The EIS is compact, rugged and does not require a pump or energy source, which makes it suitable for retrieval, military and third world needs without compromising risk.
To view a video about the operation and features of the EIS, please click here.
Marwa’s Principal has extensive experience with the Egyptian health system, as a consultant and undersecretary of health for the Egyptian Health Insurance Organization Clinics (HIO) as well as leadership positions in the Egyptian Ministry of Health.
“Marwa has presented a compelling opportunity with experienced professionals to take Analytica’s Enhanced Infusion System (EIS) into a large and growing market in the Middle East,” said Dr. Michael Monsour, Chairman of Analytica Ltd. “We look forward to working with Marwa to expand the usage of our unique EIS technology.”
For more information about Analytica and the Enhanced Infusion System, visit www.AnalyticaMedical.com
For investor or business inquiries, please contact: investorrelations@analyticamedical.com
For media inquiries, please contact: Annie Starr, astarr@6degreespr.com
About Analytica Limited
Analytica is a product development and commercialisation company based in Brisbane, Australia that is focussed on Class I and II medical device products.
Analytica is the developer of the Enhanced Infusion System (EIS), a combination of patented technologies developed under the project names AutoStart and AutoFlush. The EIS is a simple and inexpensive IV add-in technology to decrease nursing monitoring costs, reduce embolism risk, improve infection control, and automatically restart flow after medication delivery during intravenous fluid infusion.
Analytica is also the manufacturer of the PeriCoach® System, an e-health treatment system for women who suffer stress urinary incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles because of pregnancy, childbirth and menopause.
____________________
¹ Trademark of ICU Medical Australia.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d7af8a18-4b05-4cae-a8bb-71d578ab84fc
SOURCE : Analytica Limited
To view a video about the operation and features of the EIS, please click here.
Marwa’s Principal has extensive experience with the Egyptian health system, as a consultant and undersecretary of health for the Egyptian Health Insurance Organization Clinics (HIO) as well as leadership positions in the Egyptian Ministry of Health.
“Marwa has presented a compelling opportunity with experienced professionals to take Analytica’s Enhanced Infusion System (EIS) into a large and growing market in the Middle East,” said Dr. Michael Monsour, Chairman of Analytica Ltd. “We look forward to working with Marwa to expand the usage of our unique EIS technology.”
For more information about Analytica and the Enhanced Infusion System, visit www.AnalyticaMedical.com
For investor or business inquiries, please contact: investorrelations@analyticamedical.com
For media inquiries, please contact: Annie Starr, astarr@6degreespr.com
About Analytica Limited
Analytica is a product development and commercialisation company based in Brisbane, Australia that is focussed on Class I and II medical device products.
Analytica is the developer of the Enhanced Infusion System (EIS), a combination of patented technologies developed under the project names AutoStart and AutoFlush. The EIS is a simple and inexpensive IV add-in technology to decrease nursing monitoring costs, reduce embolism risk, improve infection control, and automatically restart flow after medication delivery during intravenous fluid infusion.
Analytica is also the manufacturer of the PeriCoach® System, an e-health treatment system for women who suffer stress urinary incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles because of pregnancy, childbirth and menopause.
____________________
¹ Trademark of ICU Medical Australia.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d7af8a18-4b05-4cae-a8bb-71d578ab84fc
SOURCE : Analytica Limited
Tuesday 27 April 2021
SAFR® FROM REALNETWORKS GRANTED SMALL BUSINESS INNOVATION RESEARCH CONTRACT FROM US AIR FORCE
KUALA LUMPUR, April 27 (Bernama) -- SAFR® from RealNetworks Inc, a face recognition and visual analytics platform, has been awarded its third Small Business Innovation Research (SBIR) contract from the United States Air Force (USAF).
Based on a statement, this contract enables SAFR to advance its computer vision platform to support perimeter protection and domestic search and rescue (SAR) missions.
The SBIR contract allows SAFR to enhance its platform to run on an NVIDIA® Jetson AGX Xavier™ based UGV system.
The addition of SAFR’s AI-powered analytics on autonomous and semi-autonomous robotic devices provides a force multiplier and a layer of safety for defence and civilian security and emergency services personnel.
SAFR is focused on reducing the risk service members face in their daily duties by allowing SAFR-enhanced UGVs to perform perimeter patrols and monitor contested environments.
The UGV platform will recognise when unauthorised persons are present in restricted areas.
SAFR’s solution is being extended to operate onboard UGV devices and produce patrol reports with positional data upon completion of patrol duties.
In high-risk scenarios involving SAR missions, the robotic device could locate persons using SAFR’s body detection capabilities, providing real-time alerts and access route details to speed up extraction – greatly reducing the risk for responders.
“The UGV platform equipped with SAFR AI represents the future of embedded device operations and computer vision for an emerging range of robotic systems,” said SAFR Senior Product Manager, Eric Hess.
-- BERNAMA
Based on a statement, this contract enables SAFR to advance its computer vision platform to support perimeter protection and domestic search and rescue (SAR) missions.
The SBIR contract allows SAFR to enhance its platform to run on an NVIDIA® Jetson AGX Xavier™ based UGV system.
The addition of SAFR’s AI-powered analytics on autonomous and semi-autonomous robotic devices provides a force multiplier and a layer of safety for defence and civilian security and emergency services personnel.
SAFR is focused on reducing the risk service members face in their daily duties by allowing SAFR-enhanced UGVs to perform perimeter patrols and monitor contested environments.
The UGV platform will recognise when unauthorised persons are present in restricted areas.
SAFR’s solution is being extended to operate onboard UGV devices and produce patrol reports with positional data upon completion of patrol duties.
In high-risk scenarios involving SAR missions, the robotic device could locate persons using SAFR’s body detection capabilities, providing real-time alerts and access route details to speed up extraction – greatly reducing the risk for responders.
“The UGV platform equipped with SAFR AI represents the future of embedded device operations and computer vision for an emerging range of robotic systems,” said SAFR Senior Product Manager, Eric Hess.
-- BERNAMA
ROYAL REHAB-EKSO BIONICS PARTNERSHIP EXPANDS ASIA PACIFIC ROBOTIC EXOSKELETON ADOPTION
KUALA LUMPUR, April 26 (Bernama) -- Ekso Bionics, an industry leader in exoskeleton technology, with presence in Malaysia, has announced partnership with Royal Rehab in Australia, further scaling use of its robotic exoskeleton across the Asia Pacific region.
With Ekso Bionics’ recent expansion plan in Asia Pacific, EksoNRs are now in Malaysia, Singapore, Hong Kong, Taiwan and Australia.
Ekso is the most clinically-used robotic exoskeleton globally and in Asia and has helped patients take more than 130 million steps globally, according to a statement.
Royal Rehab Chief Executive Officer, Matt Mackay said breakthroughs in technology were driving better and faster outcomes for people living with life-changing conditions and injury; however, these have been unavailable in Australia, until now.
“It is our vision to create a centre of excellence in rehabilitation technology which will empower people with disabilities with an unparalleled level of freedom, choice and independence,’’ said Mackay.
Royal Rehab, Australia’s leading not-for-profit provider of rehabilitation and disability support services, has entered into an agreement with Ekso Bionics to bring its advanced exoskeleton technology to Australia.
Royal Rehab is also in discussions with Ekso Bionics to act as the demonstration site of the EksoNR for other rehabilitation providers in the Australian market in the future.
The EksoNR is set to revolutionise rehabilitation practice in Malaysia and Asia with its ability to help improve patient recovery following stroke, acquired brain injury and spinal cord injury.
More details at www.royalrehab.com.au.
-- BERNAMA
Monday 26 April 2021
3 BITWATS EXTRAORDINARY MINING RIGS DISRUPT CRYPTO MARKET
KUALA LUMPUR, April 26 (Bernama) -- The rapidly evolving global market for cryptocurrency is currently abuzz with the recent introduction of three extraordinarily designed mining rigs namely BT, DBT and GBT from BitWats.
Instead of focusing only on highly proficient and technology savvy mining stalwarts, these products allow the casual enthusiasts as well as small-time miners to make a fortune out of crypto mining.
According to a statement, over the years, cryptocurrency mining has seen serious improvements.
However, owing to the highly technical nature of this domain, it had limited to no scope for people that are technologically challenged.
Bitwats has already changed that perception by creating three rigs that are pre-configured and just needs to be plugged in for an uncomplicated crypto mining experience.
Within less than a month in the market, BT, DBT and GBT have been used by many common users without any technical background to earn healthy returns on their investment.
The miners from Bitwats are suitable for home use because they generate low amounts of heat as well as noise. More details at https://www.bitwats.com
-- BERNAMA
Instead of focusing only on highly proficient and technology savvy mining stalwarts, these products allow the casual enthusiasts as well as small-time miners to make a fortune out of crypto mining.
According to a statement, over the years, cryptocurrency mining has seen serious improvements.
However, owing to the highly technical nature of this domain, it had limited to no scope for people that are technologically challenged.
Bitwats has already changed that perception by creating three rigs that are pre-configured and just needs to be plugged in for an uncomplicated crypto mining experience.
Within less than a month in the market, BT, DBT and GBT have been used by many common users without any technical background to earn healthy returns on their investment.
The miners from Bitwats are suitable for home use because they generate low amounts of heat as well as noise. More details at https://www.bitwats.com
-- BERNAMA
MONDE NISSIN RECEIVES PHILIPPINE STOCK EXCHANGE APPROVAL FOR PROPOSED IPO
KUALA LUMPUR, April 26 (Bernama) -- Global food and beverages company, Monde Nissin Corporation (Monde Nissin) has received the Notice of Approval from the Philippine Stock Exchange (PSE) for its proposed initial public offering of its Common Shares (the Offer).
The PSE approval comes one day after Monde Nissin received pre-effective approval from the Philippine Securities and Exchange Commission.
As previously announced, Monde Nissin plans to issue up to approximately 20 per cent of the issued and outstanding capital stock of the Company after completion of the Offer if the overallotment option is not exercised.
The Company intends to use the net proceeds from the primary offer to fund Capital Expenditure, redemption of the Arran Convertible Note, and repayment of loans to commercial banks.
The final timing of the Offer, final offer price, final number of offer shares, and allocation of the proceeds will depend on market conditions, the circumstances surrounding the Offer, and will be subject to favourably securing the remaining necessary regulatory approvals.
Monde Nissin in a statement said: “We are excited about the prospect of becoming a global public company and believe that Monde Nissin provides a compelling investment opportunity.
“We combine the stability of our Asia-Pacific Food and Beverage business and the strong positions that our noodles, crackers and baked goods have in the Philippines with the exciting growth opportunities from Quorn, which is poised to build on its loyal customers and expand its reach and product offerings to compete and win in the rapidly growing global meat alternatives market.”
UBS AG Singapore Branch, Citigroup Global Markets Limited and J.P. Morgan Securities plc will serve as Joint Global Coordinators and Joint Bookrunners for the proposed offering.
More details at www.mondenissin.com.
-- BERNAMA
ERGOMED EXPANDS OPERATIONS IN JAPAN
RNS
PRESS RELEASE
PRESS RELEASE
Ergomed expands operations in Japan
New legal entity and regional office established in Tokyo responding to client demand
Guildford, UK, April 26 (Bernama-GLOBE NEWSWIRE) -- Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces that its PrimeVigilance business, a global leader in the provision of pharmacovigilance and medical information services, has established its new legal entity and regional office in Japan and is fully operational from 26 April 2021.
The new subsidiary company, trading as PrimeVigilance Japan KK, is based in Tokyo and offers a comprehensive range of pharmacovigilance services, including a dedicated Japanese safety database. Full Japanese language Medical Information services are also provided.
This expansion provides existing and prospective international PrimeVigilance clients the opportunity to extend their product coverage into the strategically important Japanese pharmaceutical market, the fourth largest globally after the US, the EU and China. It also provides PrimeVigilance and Ergomed the opportunity to provide high quality specialist services to domestic Japanese companies, opening up a new market.
PrimeVigilance has a strong operational presence in Europe and the recent acquisitions of Ashfield PV and MedSource, as well as significant organic growth in the US, have elevated PrimeVigilance into a market leading position in North America. The new facility in Japan adds Asia to Ergomed’s global footprint, enabling PrimeVigilance to offer operational services in all major regions, with pharmacovigilance and medical information professionals based in each territory, providing both local and global expertise.
Dr Miroslav Reljanović, Executive Chairman of Ergomed, said: “Ergomed has provided a breadth of services and expertise in Asia both as a CRO and as a pharmacovigilance specialist through its outsourcing model for many years. With a solid base of international clients in Japan, Ergomed is establishing its own pharmacovigilance and medical information infrastructure to serve current and future clients and further strengthen our global operational and commercial footprint in the strategically important Asia region. Following the two US acquisitions in 2020 of Ashfield Pharmacovigilance (now PrimeVigilance USA) and MedSource, this marks another major step in our strategy to establish Ergomed as a leading international pharmaceutical services specialist.”
ENDS
Enquiries:
Ergomed plc
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Tel: +44 (0) 1483 402 975
Numis Securities Limited
Freddie Barnfield / Matthew O’Dowd (Nominated Adviser)
James Black (Broker)
Tel: +44 (0) 20 7260 1000
Consilium Strategic Communications
Chris Gardner / Matthew Neal
Olivia Manser / Angela Gray
Tel: +44 (0) 20 3709 5700
ergomed@consilium-comms.com
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical trials, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes a full range of high-quality contract research and clinical trial management (CRO) services under the Ergomed brand together with an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and an internationally recognized specialist expertise in orphan drug development, under the PSR brand. For further information, visit: http://ergomedplc.com.
SOURCE : Ergomed plc
Friday 23 April 2021
Yardi technology offers Troon Group wide investment opportunities
KUALA LUMPUR, April 22 -- Yardi(R) Investment Manager has been implemented by Troon Group with a further focus centered on attracting investors and scaling its operations.
Yardi Investment Manager offers a single connected solution improving communications with current and prospective investors and supporting the management of new investment opportunities.
According to a statement, Troon Group has been streamlining its property management operations with Yardi(R) since 2019.
The company has also benefited from accurate, real-time data, allowing staff to make well-informed decisions that support long-term plans for growth via a solution set comprising Yardi(R) Voyager, Yardi(R) Job Cost and Yardi(R) Advanced Budgeting.
It will use Yardi Investment Manager for its customer relationship, capital call and distribution activities. The solution will also give investors easy online and mobile access to investment opportunities and reports.
Yardi Vice President of International, Neal Gemassmer said: “We are pleased to aid Troon Group in capturing and executing new business. Benefits will include less time spent by staff on manual data compilation and higher transparency that attracts investors.”
Meanwhile, Troon Group Director of Asset Management, Garrath Holdstock said: “We see Yardi Investment Manager as an invaluable tool for our team and our investors. We recognised Yardi Investment Manager as the perfect opportunity for attracting new investors, matching them with opportunities and interacting with them efficiently.”
More details at https://www.yardi.asia/
-- BERNAMA
CISCO APPDYNAMICS BROADENS GLOBAL SAAS OFFERING VIA 5 NEW LOCATIONS
KUALA LUMPUR, April 22 (Bernama) -- Cisco AppDynamics, the industry leading Business Observability platform has expanded its Software-as-a-Service (SaaS) offering through five new strategic locations, enabling fast, secure and reliable access to the AppDynamics Business Observability platform.
Built on Amazon Web Services (AWS), the new locations are Cape Town (South Africa); Hong Kong (China); London (England); São Paulo (Brazil); and, Singapore, according to a statement.
This will provide regional customers and partners with access to full-stack observability solutions that are secure, scalable and adhere to their local data residency regulations, enabling companies to deliver a superior digital experience.
“AppDynamics is committed to delivering superior digital experiences through our Business Observability platform, and the expansion of our SaaS presence will provide a level of SaaS coverage unmatched in our industry,” said AppDynamics chief product officer, Vipul Shah.
The addition of five new locations offers a solution to enterprises concerned with potential data sovereignty and governance requirements, and provides access for customers worldwide.
With points of presence already in place in Portland (US), Frankfurt (Germany), Mumbai (India) and Sydney (Australia), AppDynamics now has more SaaS support than any other vendor in the market.
Recently acknowledged as a notable strength by Gartner, AppDynamics’ robust global SaaS footprint will ensure enterprise companies can focus on creating flawless digital experiences through the Cisco AppDynamics Business Observability platform.
The addition of the five new locations comes on the heels of AppDynamics’ SaaS offering in India, announced in October last year, and builds on the company’s global SaaS footprint across Africa, Asia, Europe and South America.
-- BERNAMA
Subscribe to:
Posts (Atom)